Die Ophthalmologie最新文献

[New systemic treatment approaches for conjunctival melanoma].

Die Ophthalmologie Pub Date : 2025-03-11 DOI: 10.1007/s00347-025-02207-9

Florian T Steinberg, Michael Simon, Philomena A Wawer-Matos Reimer, Alexander C Rokohl, Ludwig M Heindl

{"title":"[New systemic treatment approaches for conjunctival melanoma].","authors":"Florian T Steinberg, Michael Simon, Philomena A Wawer-Matos Reimer, Alexander C Rokohl, Ludwig M Heindl","doi":"10.1007/s00347-025-02207-9","DOIUrl":"https://doi.org/10.1007/s00347-025-02207-9","url":null,"abstract":"Conjunctival melanoma is a rare disease that nevertheless has a high tumor-associated mortality rate. A resection in sano with adjuvant local treatment currently represents the therapeutic gold standard and systemic treatment is used for metastasized conjunctival melanoma and/or very advanced nonresectable local findings. New knowledge on molecular changes in conjunctival melanoma shows a clear similarity to those of cutaneous melanoma. Therefore, many findings on new systemic forms of treatment for cutaneous melanoma can be transferred to conjunctival melanoma. In the clinical application BRAF/MEK inhibitors and immune checkpoint inhibitors are already in use and good response rates have been shown in small retrospective studies and case reports. Due to the rarity of conjunctival melanoma, there are no larger prospective studies comparing different systemic therapeutic agents. In a nonrandomized retrospective comparison, a better overall survival was shown for a combination of BRAF/MEK inhibitors (progression-free 1‑year survival probability of 54.7%; overall survival of 29.1 months) compared to a combination of PD1/CTLA4 antibodies (progression-free 1‑year survival probability of 42%; overall survival of 18 months). The current recommendation is to perform genomic profiling for every conjunctival melanoma, particularly to investigate a BRAF mutation. If a BRAF mutation is present, BRAF/MEK inhibitor treatment should preferably be initiated. Treatment with immune checkpoint inhibitors can be used in the case of BRAF-negative mutation status or treatment failure with BRAF/MEK inhibitors. Monotherapy with the CTLA4 antibody ipilimumab is not recommended due to its inferiority to PD1 antibodies. New knowledge in the genomic profiling of conjunctival melanoma could enable further targeted treatment options in the future.","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Assistance systems and fitness to drive in case of visual field defects : Statement of the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Status: 21 January 2025].

Die Ophthalmologie Pub Date : 2025-03-10 DOI: 10.1007/s00347-025-02204-y

引用次数: 0

[Bilateral diffuse uveal melanocytic proliferation (BDUMP) as initial manifestation of an endocrine bronchial carcinoma].

Die Ophthalmologie Pub Date : 2025-03-07 DOI: 10.1007/s00347-025-02213-x

Katharina Wall, Karin U Löffler, Thomas Ach

引用次数: 0

[Sting of a honeybee in the cornea-Case report and review of the literature].

Die Ophthalmologie Pub Date : 2025-03-07 DOI: 10.1007/s00347-025-02200-2

Kristóf Márton Vörös, Júlia Katalin Török, Maria Della Volpe-Waizel, Fabian Norbert Fries, Zoltán Zsolt Nagy, Nóra Szentmáry

引用次数: 0

[Bilateral optic nerve atrophy of unknown etiology].

Die Ophthalmologie Pub Date : 2025-03-07 DOI: 10.1007/s00347-025-02210-0

Tyll Jandewerth, Klemens Paul Kaiser, Thomas Kohnen, Sandra Liakopoulos

引用次数: 0

[Cataract surgery in sub-Saharan Africa-Possibilities and limits].

Die Ophthalmologie Pub Date : 2025-03-06 DOI: 10.1007/s00347-025-02195-w

Stephan Irle, Hanne Irle, Rohil Paes, Piet Noë

{"title":"[Cataract surgery in sub-Saharan Africa-Possibilities and limits].","authors":"Stephan Irle, Hanne Irle, Rohil Paes, Piet Noë","doi":"10.1007/s00347-025-02195-w","DOIUrl":"https://doi.org/10.1007/s00347-025-02195-w","url":null,"abstract":"Background: The importance of cataract surgery for the treatment of visual impairment and blindness is as uncontroversial as the cost-effectiveness of the procedure. In terms of quality, there are almost no published case series of cataract operations in sub-Saharan Africa that meet the World Health Organization (WHO) guidelines for postoperative visual acuity.Objective: The results after cataract surgery at a publicly accessible tertiary care eye clinic in Rwanda are presented and compared with standardized results from an eye clinic in Germany (AKW).Methods: Data from 100 consecutive eyes (manual small incision cataract surgery, MSICS-Rwanda, Phaco-Rwanda, Phaco-AKW) were retrospectively evaluated. The results were compared with each other and with WHO guidelines.Results: The number of patients with significantly reduced preoperative visual acuity (visual acuity > 1.3 logMAR) was highest in the MSICS group (MSICS 92%, Phaco-Rwanda 13%, Phaco-AKW 1%). Uncorrected postoperative visual acuity was similar in the Phako-Rwanda and Phako-AKW groups (0.22/0.21 logMAR) and better than MSICS Rwanda (0.33 logMAR). The best corrected postoperative visual acuity was significantly better in the Phako-Rwanda group (0.07 logMAR) than in the two comparison groups Phako-AKW (0.1 logMAR) and MSICS Rwanda (0.15 logMAR). The results of all three groups fulfilled the WHO criteria for postoperative visual acuity.Conclusion: Despite poor initial visual acuity, high quality results can be achieved in cataract surgery in a clinical setting in sub-Saharan Africa that are within WHO expectations. A coexistence of MSICS technique and phaco seems reasonable to avoid complications and achieve the best possible results.","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143574814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Erratum zu: Augeninnendruckentgleisung, Hyphäma und Uveitis bei chronischer lymphatischer Leukämie unter Ibrutinib-Therapie.

Die Ophthalmologie Pub Date : 2025-03-06 DOI: 10.1007/s00347-025-02208-8

Abdelrahman Assaf, Fidan Aghayeva, Ines M Lanzl

引用次数: 0

[A rare retinal finding: acute exudative polymorphous vitelliform maculopathy-Image and case].

Die Ophthalmologie Pub Date : 2025-03-06 DOI: 10.1007/s00347-025-02196-9

Bettina Isabel Deak, Albrecht Lommatzsch, Christos Haritoglou

引用次数: 0

[Our experiences of the European Glaucoma Society (EGS) Residents' Course 2024 in Lisbon]. [我们在里斯本参加欧洲青光眼协会（EGS）2024 年住院医师课程的经历]。

Die Ophthalmologie Pub Date : 2025-03-05 DOI: 10.1007/s00347-025-02206-w

Julia Prinz, Raoul Verma-Fuehring

引用次数: 0

[Neurotrophic keratopathy and corneal ulcers in diabetes mellitus].

Die Ophthalmologie Pub Date : 2025-03-05 DOI: 10.1007/s00347-025-02198-7

C Haubold, H Agostini, T Reinhard, D Böhringer

{"title":"[Neurotrophic keratopathy and corneal ulcers in diabetes mellitus].","authors":"C Haubold, H Agostini, T Reinhard, D Böhringer","doi":"10.1007/s00347-025-02198-7","DOIUrl":"https://doi.org/10.1007/s00347-025-02198-7","url":null,"abstract":"Diabetes mellitus is a chronic metabolic disease associated with numerous complications, including diabetic keratopathy. This frequently underestimated disease can lead to reduced corneal sensitivity, neurotrophic ulcers and potentially sight-threatening infections. In this retrospective analysis of the subgroup of 136,992 machine-readable health records recruited from all patients who presented to our university outpatient clinic between January 2003 and February 2024, we investigated the association between diabetes mellitus, neurotrophic keratopathy and corneal ulcers. Of the patients 3168 had corneal ulcers (prevalence 2.3%) and 11,338 had diabetes mellitus (8%). The results showed that diabetes mellitus significantly increased the risk of corneal ulcers (odds ratio, OR 1.18; 95% confidence interval, CI 1.04-1.32) and neurotrophic keratopathy (OR 1.78; 95% CI 1.20-2.56). In addition, older age and male gender were risk factors. In the reverse analysis, corneal ulcers were shown to be significant predictors of the presence of diabetes mellitus. Our results underline the need for regular ophthalmological check-ups and diabetes mellitus screening in patients with corneal complications in order to intervene at an early stage and prevent severe consequences such as loss of vision.","PeriodicalId":72808,"journal":{"name":"Die Ophthalmologie","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143560251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0